Target Sequencing and Resequencing Market (By Technology: Sequencing, Re-sequencing; By Application: Clinical application, Plant and animal sciences, Drug development, Others; By Type: DNA-based targeted sequencing, RNA-based targeted sequencing; By End-Use: Hospitals & clinics, Academic research, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global target sequencing and resequencing market size was exhibited at USD 5.99 billion in 2022 and is projected to hit around USD 47.75 billion by 2032, growing at a CAGR of 23.07% during the forecast period 2023 to 2032.

Key Pointers:

• North American region dominated the market and generated more than 50.4% of the revenue share in 2022.
• By Technology, the sequencing segment contributed more than 72.7% of revenue share in 2022.
• By Application, the clinical segment dominated the market in 2022.
• By Type, the DNA-based segment captured for the maximum market share in 2022. 
• By End-use, the academic study segment generated more than 50.9% of the revenue share in 2022.

Target Sequencing and Resequencing Market Report Scope

The continuous technological developments in genome sequencers along with broad applications and adoption of NGS technology is expected drive the market growth. Furthermore, the increasing application of NGS in molecular diagnostics and precision medicione is also anticipated to create growth opportunities for market growth.

NGS is expected to witness increasing adoption in various disease conditions and infectious disease treatment, along with Noninvasive Prenatal Testing, transplant medicine, and pharmacogenomics. Targeted gene panels and gene expression profiling through qPCR remain the two most common applications for NGS sequencers in a pathology laboratory. While oncology remains a primary area of NGS use in clinics, pathologists are expected to adopt it in other areas too over the coming years. Such factors are expected to boost market growth in the forecast period.

On the other hand, the introduction of novel products is expected to boost targeted sequencing and resequencing market growth. For instance, in October 2022, the Illumina genomics Forum introduced the NovaSeq X, which can run around 20,000 whole genomes a year on one system. This novel system has 10 billion flow cells. When run at 2×150 base pair reads, it will output 6 TB. Moreover, in December 2021, F. Hoffmann-La Roche AG launched the AVENIO Edge System for simplifying the automation of NGS sample preparation and driving advancements in precision medicine. This novel system is a pre-analytical platform that offers end-to-end, integrated, consistently high-quality outcomes.

Key entities in the targeted sequencing & resequencing market are focusing on collaboration to strengthen their market position. For instance, in March 2021, Illumina collaborated with Geneseeq to commercialize and develop IVD NGS kits in China for cancer care. This novel kit was developed by using Illumina’s NextSeq 550Dx sequencing system, which was approved by China’s NMPA (National Medical Products Administration). Moreover, in March 2021, Hackensack Meridian Health and Genomic Testing Cooperative (GTC) entered into a partnership to establish an oncology-focused RNA and DNA sequencing laboratory in the U.S. This lab—Anthology Diagnostics—will perform NGS of cell-free DNA from liquid biopsy samples and DNA/RNA from tumor samples.

Some of the prominent players in the Target Sequencing and Resequencing Market include:

• Illumina, Inc.
• Agilent Technologies
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd
• DNASTAR Inc.
• Bio-Rad Laboratories, Inc.
• PacBio
• Integrated DNA Technologies, Inc.
• RainDance Technologies, Inc.
• Perkin Elmer, Inc.
• BGI
• PierianDx
• Genomatix GmbH
• GATC Biotech Ag
• Macrogen, Inc.
• QIAGEN
• Oxford Nanopore Technologies

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Target Sequencing and Resequencing market.

By Technology

• Sequencing
• Re-sequencing
• Electrophoresis-based resequencing
• NGS
• Array-based resequencing

By Application

• Clinical application
• Plant and animal sciences
• Drug development
• Others

By Type

DNA-based targeted sequencing

RNA-based targeted sequencing

By End-Use

• Hospitals & clinics
• Academic research
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)